P. Kent Hawryluk, President & CEO at MBX Biosciences, Inc. (MBX), bought 37,000 shares at $28.41 ($1.1M) on 2026-03-13, disclosed to the SEC on 2026-03-16.
MBX Biosciences President and CEO Kent Hawryluk purchased 18,500 shares at $28.41, signaling confidence in the biotech's pipeline despite recent volatility. This buy comes as the stock has surged 242.53% over the last year but pulled back 21.76% over the past month.
The shares are currently trading at $29.80, reflecting a 6.66% gain over the last five days but a significant 21.76% decline over the past month. Despite a massive 242.53% one-year rally, the stock remains 33.62% below its 52-week high of $44.89.
Catalysts include the Obesity Day event on May 11, 2026, where preliminary clinical data for MBX 4291 will be presented, and the Phase 3 plans for canvuparatide announced on March 16, 2026.
The stock carries a high short interest of 11.9%, and the recent resignation of the CFO on March 7, 2026, raises questions about management stability and execution.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $28.41 | 18,500 | $526K | 50.0% |
| 2 | $28.41 | 18,500 | $526K | 50.0% |
| Total | $28.41 avg | 37,000 | $1.1M | 100% |
| Filing → |
| MBX | BUY | 2025-02-05 | $535K | — | Filing → |
| GEMP | BUY | 2017-03-14 | $474K | — | Filing → |
| GEMP | BUY | 2016-08-12 | $250K | — | Filing → |